MedTrace Logo

"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

NCT03510637 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 7500

Last updated 2019-07-29

No results posted yet for this study

Summary

The primary purpose of the ANRS 12332 HepNile study cohort is to assess in "Real-Life" condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs) introduced in the Egyptian National Treatment Programme for the treatment of Chronic Hepatitis C (CHC).

Conditions

  • Chronic Hepatitis C

Sponsors & Collaborators

  • Institut Pasteur

    collaborator INDUSTRY

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Yehia Mohamed El Sayed El Shazly, MD · Ain Shams University

  • Arnaud Fontanet, MD, PhD · Institut Pasteur

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510637 on ClinicalTrials.gov